Candel Therapeutics (CADL) EPS (Weighted Average and Diluted) (2021 - 2023)
Historic EPS (Weighted Average and Diluted) for Candel Therapeutics (CADL) over the last 3 years, with Q4 2023 value amounting to -$0.38.
- Candel Therapeutics' EPS (Weighted Average and Diluted) fell 12352.94% to -$0.38 in Q4 2023 from the same period last year, while for Dec 2023 it was -$1.3, marking a year-over-year decrease of 10312.5%. This contributed to the annual value of -$1.74 for FY2024, which is 3282.44% down from last year.
- According to the latest figures from Q4 2023, Candel Therapeutics' EPS (Weighted Average and Diluted) is -$0.38, which was down 12352.94% from -$0.29 recorded in Q3 2023.
- In the past 5 years, Candel Therapeutics' EPS (Weighted Average and Diluted) registered a high of $0.51 during Q4 2021, and its lowest value of -$1.46 during Q2 2021.
- Its 3-year average for EPS (Weighted Average and Diluted) is -$0.33, with a median of -$0.3 in 2022.
- As far as peak fluctuations go, Candel Therapeutics' EPS (Weighted Average and Diluted) surged by 9041.1% in 2022, and later plummeted by 90000.0% in 2023.
- Candel Therapeutics' EPS (Weighted Average and Diluted) (Quarter) stood at $0.51 in 2021, then crashed by 133.33% to -$0.17 in 2022, then tumbled by 123.53% to -$0.38 in 2023.
- Its EPS (Weighted Average and Diluted) stands at -$0.38 for Q4 2023, versus -$0.29 for Q3 2023 and -$0.33 for Q2 2023.